2019
DOI: 10.3892/ol.2019.10359
|View full text |Cite
|
Sign up to set email alerts
|

EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2/STAT3 signaling pathway

Abstract: The aim of the current study was to investigate the role of enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) in the progression of bladder cancer. Human bladder cancer tissue samples were analyzed by immunohistochemistry, and the association between the clinicopathological parameters and EZH2 expression was analyzed. The proliferation, apoptosis and migration ability of the human bladder cancer cell lines E-J and 5637 with or without the EZH2 inhibitor UNC1999 was investigated. The effect of UN… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
25
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 32 publications
(28 citation statements)
references
References 45 publications
3
25
0
Order By: Relevance
“…One of the issues in treatment of patients with BC is the high metastatic capability of BC cells that negatively affects overall survival of patients with this life-threatening disorder, and remarkably reduces efficacy of chemotherapy and radiotherapy, since cancer cells migrate in neighboring and distant tissues, providing problems with their effective eradication [ 26 , 27 , 28 ]. Several molecular pathways such as ZEB1 [ 19 ], EZH2 [ 29 ], PI3K/Akt [ 30 ], and so on have been identified as potential factors involved in metastasis and invasion of BC cells. Epithelial-to-mesenchymal transition (EMT) is one of the most important molecular pathways that enhanced migratory ability of cancer cells [ 31 , 32 ].…”
Section: Introductionmentioning
confidence: 99%
“…One of the issues in treatment of patients with BC is the high metastatic capability of BC cells that negatively affects overall survival of patients with this life-threatening disorder, and remarkably reduces efficacy of chemotherapy and radiotherapy, since cancer cells migrate in neighboring and distant tissues, providing problems with their effective eradication [ 26 , 27 , 28 ]. Several molecular pathways such as ZEB1 [ 19 ], EZH2 [ 29 ], PI3K/Akt [ 30 ], and so on have been identified as potential factors involved in metastasis and invasion of BC cells. Epithelial-to-mesenchymal transition (EMT) is one of the most important molecular pathways that enhanced migratory ability of cancer cells [ 31 , 32 ].…”
Section: Introductionmentioning
confidence: 99%
“…In colorectal cancer, this pathway influences tumor cell activity by regulating the expression of BCL2, E-cadherin, and VEGF, among others,8 while in ovarian cancer, activated STAT3 can promote the occurrence of EMT through the JAK2/STAT3/Snail signaling pathway 9. Furthermore, albumin can induce cell proliferation and transdifferentiation of renal tubular epithelial cells by activating the JAK2/STAT3 signaling pathway 10. However, reports on the correlation between JAK2/STAT3 signaling and EMT in lung adenocarcinoma are limited…”
Section: Introductionmentioning
confidence: 99%
“…On the other hand, previous studies have provided some potential targets of miR-605, such as tumor necrosis factor α-induced protein 3, EN2, enhancer of zeste 2 (EZH2) and forkhead Box P1, which mediate the functional effects of miR-605 in human malignancies ( 18 , 19 , 37 , 38 ). EZH2 is a widely investigated oncogene in several human malignancies, such as non-small cell lung cancer and bladder cancer ( 39 , 40 ). In OS tissues, EZH2 has been found to be upregulated and associated with aggressive tumor behavior and poor prognosis and the knockdown of EZH2 could significantly inhibit OS cell proliferation, migration and invasion ( 31 ).…”
Section: Discussionmentioning
confidence: 99%